Adaptive Biotechnologies Corporation (ADPT)
Summary
Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder
Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the spin-off of Immune Medicine revealing strong underlying profitability. MRD revenue grew 49% year-over-year (excluding milestones), sequencing gross margins exceeded 70%, and adjusted EBITDA margin reached 14%, supporting a high-growth, high-quality earnings profile. Refinancing eliminated a 5% perpetual revenue burden, while the planned separation of Immune Medicine should clarify earnings and remove $6M in quarterly adjusted EBITDA losses.
Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 3,325 | $99,894.7 | $81,795 | -$18,099.7 | -18.12% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 3,182 | $273,018.78 | $79,327.26 | -$193,691.52 | -70.94% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 9 | $522.24 | $227.25 | -$294.99 | -56.49% |
| NA Nizar Araji National Bank Of Canada /FI/ | 56.5 | $1,143.83 | $1,408.54 | $264.71 | 23.14% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 36,430.5 | $3.12M | $908,212.36 | -$2.21M | -70.88% |
Adaptive Biotechnologies Corporation Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SN Subbu Nambi Guggenheim | 578.95 | $11,613.67 | $13,037.92 | $1,424.25 | 12.26% |
 Mark Massaro BTIG | - | - | - | - | - |
Adaptive Biotechnologies Corporation (ADPT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Adaptive Biotechnologies Corporation ever had a stock split?
Adaptive Biotechnologies Corporation Profile
| Biotechnology Industry | Healthcare Sector | Chad Robins CEO | NASDAQ (NGS) Exchange | 00650F109 CUSIP |
| US Country | 624 Employees | - Last Dividend | 15 Jul 2026 Last Split | 27 Jun 2019 IPO Date |
Overview
Adaptive Biotechnologies Corporation stands as a pivotal entity within the medical field, operating at a commercial stage to revolutionize the approach to diagnosing and treating an array of diseases through its benchmark immune medicine platform. Established in 2009 and originally named Adaptive TCR Corporation, the company transitioned to its current designation in December 2011. Its headquarters are strategically positioned in Seattle, Washington. The foundation of Adaptive Biotechnologies’ operations rests on leveraging sophisticated immunosequencing technologies, synergized with proprietary chemistry, computational biology, and advanced machine learning. These hybrid technologies are meticulously engineered to unravel the complexities of the adaptive immune system, transforming raw clinical immunomics data into actionable insights. Furthermore, the company embarks on strategic collaborations with industry giants such as Genentech, Inc., for the pioneering development of neoantigen directed T cell therapies aimed at a spectrum of cancers, and with Microsoft Corporation, to forge ahead in the development of groundbreaking diagnostic tests capable of early disease detection from merely a single blood sample.
Products and Services
- Immunosequencing Platform:
This flagship platform encapsulates a conglomerate of proprietary chemistry, computational biology, and machine learning technologies designed to decode the intricacies of the adaptive immune system. It generates invaluable clinical immunomics data that provides a deeper understanding of disease mechanisms, thereby serving as a cornerstone for diagnosing and formulating targeted treatment strategies.
- clonoSEQ Diagnostic Test:
A pivotal innovation by Adaptive Biotechnologies, the clonoSEQ diagnostic test stands at the forefront of cancer management by enabling the detection and meticulous monitoring of Minimal Residual Disease (MRD). MRD represents the minuscule number of cancer cells that persist in a patient’s body during and post-treatment, marking a revolutionary step in understanding the effectiveness of cancer therapies and guiding future treatment decisions.
- Life Sciences Research:
Adaptive Biotechnologies extends its technological expertise to empower life sciences research. By providing tools and insights into the adaptive immune response, the company enhances the understanding of how the immune system interacts with various diseases, thereby facilitating breakthrough discoveries in immunology and related fields.
- Clinical Diagnostics:
The company leverages its advanced technologies to offer cutting-edge clinical diagnostics solutions. These solutions are pivotal in detecting and monitoring diseases, enabling healthcare providers to make informed decisions based on precise, real-time data regarding a patient’s immunological status.
- Drug Discovery Applications:
In the realm of drug discovery, Adaptive Biotechnologies offers a suite of applications that utilize the company’s comprehensive understanding of the adaptive immune system. This facilitates the identification of novel targets and the development of new therapeutics, accelerating the path to effective treatments for various diseases.
